Acta Diabetologica

, Volume 56, Issue 3, pp 281–288 | Cite as

Screening of HNF1A and HNF4A mutation and clinical phenotype analysis in a large cohort of Chinese patients with maturity-onset diabetes of the young

  • Xiaojing Wang
  • Tong Wang
  • Miao Yu
  • Huabing Zhang
  • Fan Ping
  • Qian Zhang
  • Jianping Xu
  • Kai Feng
  • Xinhua XiaoEmail author
Original Article



The study aimed to screen the HNF1A and HNF4A mutation in a large Chinese cohort of high clinical suspicion of maturity-onset diabetes of the young (MODY) patients and characterize the clinical features of those patients. The performance of hsCRP as a biomarker to differentiate MODY3 from early onset T2DM was also evaluated.


A total of 74 patients with a strong clinical suspicion of MODY from 59 families and 33 newly diagnosed early-onset T2DM were included. HNF1A and HNF4A mutations were analyzed by Sanger sequencing. ROC curves were used to identify the optimal cutoff of hsCRP.


One novel (c.864_865insG) and six recurrent HNF1A mutations (R203H, R263H, P379T, L422P, P519L and c.873delC) in 17 patients from 8 families (13.6%), as well as one novel HNF4A (R331H) mutation were identified. Nonspecific clinical presentations were observed in MODYX compared to MODY3 patients. MODY3 subjects exhibited with younger, lower BMI, TG, fasting and postprandial C-peptide, higher HDL than T2DM. Particularly, we confirmed serum hsCRP was lower in MODY3 than T2DM. ROC curve showed a good discrimination with an AUC of 0.852 and identified a cutoff hsCRP of 0.79 (75% sensitivity and 83% specificity). Good glycemic control was observed in all identified patients after switching to glimepiride therapy.


The prevalence of HNF1A mutation was relatively lower in Mainland China and HNF4A mutation was rare. Serum hsCRP concentrations performed well in discriminating MODY3 from T2DM. Molecular diagnosis of MODY3/1 did transform management in clinical practice and facilitated the glycemic control.


Maturity-onset diabetes of the young HNF1A HNF4A CRP Mutation 



The study was funded by research grants from the National Key R&D program of China (2017YFC1309603), National Key research and Development Program of China (2016YFA0101002), National Natural Science Foundation of China (NO. 81170736, 81570715), and Beijing science and technology project (D141107005314002). We thank all the subjects in this study.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical standard

All procedures performed in this study involving human participants were in accordance with the ethical standards of the Peking Union Medical College Hospital Ethics Committee.

Human and animal rights

The study was conducted in accordance with the principles of the Declaration of Helsinki of 1975, as revised in 2008.

Informed consent

Informed consent was obtained from all patients for being included in the study.


  1. 1.
    Velho G, Froguel P (1998) Genetic, metabolic and clinical characteristics of maturity onset diabetes of the young. Eur J Endocrinol 138:233–239CrossRefPubMedGoogle Scholar
  2. 2.
    Gardner DS, Tai ES (2012) Clinical features and treatment of maturity onset diabetes of the young (MODY). Diabetes Metab Syndr Obes 5:101–108CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Kleinberger JW, Pollin TI (2015) Undiagnosed MODY: time for action. Curr Diab Rep 15:110CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Ng MC, Lee SC, Ko GT, Li JK, So WY, Hashim Y et al (2001) Familial early-onset type 2 diabetes in Chinese patients: obesity and genetics have more significant roles than autoimmunity. Diabetes Care 24:663–671CrossRefPubMedGoogle Scholar
  5. 5.
    Xu JY, Chan V, Zhang WY, Wat NM, Lam KS (2002) Mutations in the hepatocyte nuclear factor-1alpha gene in Chinese MODY families: prevalence and functional analysis. Diabetologia 45:744–746CrossRefPubMedGoogle Scholar
  6. 6.
    Xu JY, Dan QH, Chan V, Wat NM, Tam S, Tiu SC et al (2005) Genetic and clinical characteristics of maturity-onset diabetes of the young in Chinese patients. Eur J Hum Genet 13:422–427CrossRefPubMedGoogle Scholar
  7. 7.
    Shields BM, Hicks S, Shepherd MH, Colclough K, Hattersley AT, Ellard S (2010) Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia 53:2504–2508CrossRefPubMedGoogle Scholar
  8. 8.
    Isomaa B, Henricsson M, Lehto M, Forsblom C, Karanko S, Sarelin L (1998) Chronic diabetic complications in patients with MODY3 diabetes. Diabetologia 41:467–473CrossRefPubMedGoogle Scholar
  9. 9.
    Sovik O, Njolstad P, Folling I, Sagen J, Cockburn BN, Bell GI (1998) Hyperexcitability to sulphonylurea in MODY3. Diabetologia 41:607–608CrossRefPubMedGoogle Scholar
  10. 10.
    Hu C, Jia W (2018) Diabetes in China: epidemiology and genetic risk factors and their clinical utility in personalized medication. Diabetes 67:3–11CrossRefPubMedGoogle Scholar
  11. 11.
    Timsit J, Saint-Martin C, Dubois-Laforgue D, Bellanne-Chantelot C (2016) Searching for maturity-onset diabetes of the young (MODY): when and what for? Can J Diabetes 40:455–461CrossRefPubMedGoogle Scholar
  12. 12.
    Thanabalasingham G, Shah N, Vaxillaire M, Hansen T, Tuomi T, Gasperikova D et al (2011) A large multi-centre European study validates high-sensitivity C-reactive protein (hsCRP) as a clinical biomarker for the diagnosis of diabetes subtypes. Diabetologia 54:2801–2810CrossRefPubMedGoogle Scholar
  13. 13.
    Owen KR, Thanabalasingham G, James TJ, Karpe F, Farmer AJ, McCarthy MI et al (2010) Assessment of high-sensitivity C-reactive protein levels as diagnostic discriminator of maturity-onset diabetes of the young due to HNF1A mutations. Diabetes Care 33:1919–1924CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Gragnoli C, Cockburn BN, Chiaramonte F, Gorini A, Marietti G, Marozzi G et al (2001) Early-onset type II diabetes mellitus in Italian families due to mutations in the genes encoding hepatic nuclear factor 1 alpha and glucokinase. Diabetologia 44:1326–1329CrossRefPubMedGoogle Scholar
  15. 15.
    Pihoker C, Gilliam LK, Ellard S, Dabelea D, Davis C, Dolan LM et al (2013) Prevalence, characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1A, HNF4A, and glucokinase: results from the SEARCH for diabetes in youth. J Clin Endocrinol Metab 98:4055–4062CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Harries LW, Ellard S, Stride A, Morgan NG, Hattersley AT (2006) Isomers of the TCF1 gene encoding hepatocyte nuclear factor-1 alpha show differential expression in the pancreas and define the relationship between mutation position and clinical phenotype in monogenic diabetes. Hum Mol Genet 15:2216–2224CrossRefPubMedGoogle Scholar
  17. 17.
    Schober E, Rami B, Grabert M, Thon A, Kapellen T, Reinehr T et al (2009) Phenotypical aspects of maturity-onset diabetes of the young (MODY diabetes) in comparison with type 2 diabetes mellitus (T2DM) in children and adolescents: experience from a large multicentre database. Diabet Med 26:466–473CrossRefPubMedGoogle Scholar
  18. 18.
    Bjørkhaug L, Sagen JV, Thorsby P, Søvik O, Molven A, Njølstad PR (2003) Hepatocyte nuclear factor-1 alpha gene mutations and diabetes in Norway. J Clin Endocrinol Metab 88:920–931CrossRefPubMedGoogle Scholar
  19. 19.
    Costa A, Bescós M, Velho G, Chêvre J, Vidal J, Sesmilo G et al (2000) Genetic and clinical characterisation of maturity-onset diabetes of the young in Spanish families. Eur J Endocrinol 142:380–386CrossRefPubMedGoogle Scholar
  20. 20.
    Johansen A, Ek J, Mortensen HB, Pedersen O, Hansen T (2005) Half of clinically defined maturity-onset diabetes of the young patients in Denmark do not have mutations in HNF4A, GCK, and TCF1. J Clin Endocrinol Metab 90:4607–4614CrossRefPubMedGoogle Scholar
  21. 21.
    Bitterman O, Tinto N, Franzese A, Iafusco F, Festa C, Mozzillo E et al (2018) Glucokinase deficit and birthweight:does maternal hyperglycemia always meet fetal needs? Acta Diabetol. PubMedGoogle Scholar
  22. 22.
    Ellard S, Colclough K (2006) Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1 alpha (HNF1A) and 4 alpha (HNF4A) in maturity-onset diabetes of the young. Hum Mutat 27:854–869CrossRefPubMedGoogle Scholar
  23. 23.
    Thanabalasingham G, Owen KR (2011) Diagnosis and management of maturity onset diabetes of the young (MODY). BMJ 343:d6044CrossRefPubMedGoogle Scholar
  24. 24.
    Nishikawa T, Hagihara K, Serada S, Isobe T, Matsumura A, Song J et al (2008) Transcriptional complex formation of c-Fos, STAT3, and hepatocyte NF-1 alpha is essential for cytokine-driven C-reactive protein gene expression. J Immunol 180:3492–3501CrossRefPubMedGoogle Scholar
  25. 25.
    McDonald TJ, Shields BM, Lawry J, Owen KR, Gloyn AL, Ellard S et al (2011) High-sensitivity CRP discriminates HNF1A-MODY from other subtypes of diabetes. Diabetes Care 34:1860–1862CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Delvecchio M, Salzano G, Bonura C, Cauvin V, Cherubini V, d’Annunzio G et al (2018) Can HbA1c combined with fasting plasma glucose help to assess priority for GCK-MODY vs HNF1A-MODY genetic testing? Acta Diabetol 55:981–983CrossRefPubMedGoogle Scholar
  27. 27.
    Pearson ER, Starkey BJ, Powell RJ, Gribble FM, Clark PM, Hattersley AT (2003) Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet 362:1275–1281CrossRefPubMedGoogle Scholar
  28. 28.
    Shepherd M, Shields B, Ellard S, Rubio-Cabezas O, Hattersley AT (2009) A genetic diagnosis of HNF1A diabetes alters treatment and improves glycaemic control in the majority of insulin-treated patients. Diabet Med 26:437–441CrossRefPubMedGoogle Scholar
  29. 29.
    Pearson ER, Pruhova S, Tack CJ, Johansen A, Castleden HA, Lumb PJ et al (2005) Molecular genetics and phenotypic characteristics of MODY caused by hepatocyte nuclear factor 4alpha mutations in a large European collection. Diabetologia 48:878–885CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia S.r.l., part of Springer Nature 2018

Authors and Affiliations

  1. 1.Key Laboratory of Endocrinology, Department of Endocrinology, Ministry of Health, Peking Union Medical College HospitalDiabetes Research Center of Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina

Personalised recommendations